DB:HO5

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

China Tian Yuan Healthcare Group

Executive Summary

China Tian Yuan Healthcare Group Limited, an investment holding company, provides hospitality related services in Hong Kong, Korea, the United States, the British Virgin Island, China, Singapore, and Spain.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has China Tian Yuan Healthcare Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HO5's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.0%

HO5

-2.4%

DE Hospitality

-0.6%

DE Market


1 Year Return

125.0%

HO5

-35.6%

DE Hospitality

3.0%

DE Market

Return vs Industry: HO5 exceeded the German Hospitality industry which returned -35.6% over the past year.

Return vs Market: HO5 exceeded the German Market which returned 3% over the past year.


Shareholder returns

HO5IndustryMarket
7 Day7.0%-2.4%-0.6%
30 Day28.6%-18.4%-0.1%
90 Day385.7%2.7%16.4%
1 Year125.0%125.0%-32.8%-35.6%5.2%3.0%
3 Year-42.3%-42.3%-50.4%-57.2%1.0%-6.9%
5 Year-15.5%-15.5%-50.4%-60.9%8.0%-6.4%

Price Volatility Vs. Market

How volatile is China Tian Yuan Healthcare Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is China Tian Yuan Healthcare Group undervalued compared to its fair value and its price relative to the market?

1.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HO5's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HO5's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HO5 is unprofitable, so we can't compare its PE Ratio to the DE Hospitality industry average.

PE vs Market: HO5 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HO5's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HO5 is good value based on its PB Ratio (1.6x) compared to the DE Hospitality industry average (2.1x).


Next Steps

Future Growth

How is China Tian Yuan Healthcare Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

114.7%

Forecasted Consumer Services industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Tian Yuan Healthcare Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Tian Yuan Healthcare Group performed over the past 5 years?

2.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HO5 is currently unprofitable.

Growing Profit Margin: HO5 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HO5 is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare HO5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HO5 is unprofitable, making it difficult to compare its past year earnings growth to the Hospitality industry (-15.6%).


Return on Equity

High ROE: HO5 has a negative Return on Equity (-19.92%), as it is currently unprofitable.


Next Steps

Financial Health

How is China Tian Yuan Healthcare Group's financial position?


Financial Position Analysis

Short Term Liabilities: HO5's short term assets (HK$304.1M) exceed its short term liabilities (HK$29.1M).

Long Term Liabilities: HO5's short term assets (HK$304.1M) exceed its long term liabilities (HK$17.5M).


Debt to Equity History and Analysis

Debt Level: HO5 is debt free.

Reducing Debt: HO5 has no debt compared to 5 years ago when its debt to equity ratio was 5.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if HO5 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HO5 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is China Tian Yuan Healthcare Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HO5's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HO5's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HO5's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HO5's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: HO5 is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HO5's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average board tenure


CEO

Xian Zhang (35yo)

no data

Tenure

HK$4,000,000

Compensation

Ms. Xian Zhang has been an Executive Director of China Tian Yuan Healthcare Group Limited since August 19, 2016 and has been its Chief Executive Officers. Ms. Zhang engages in investment banking and privat ...


Board Members

NamePositionTenureCompensationOwnership
Xian Zhang
CEO & Executive Directorno dataHK$4.00mno data
Hua Bing Wang
Executive Chairman0.33yrno datano data
Jingbin Guo
Independent Non-Executive Director3.92yrsHK$180.00kno data
Bai He Hu
Independent Non-Executive Director3.92yrsHK$180.00kno data
Kwok Kuen Yuen
Independent Non-Executive Director3.92yrsHK$180.00kno data
Mei He
Non-Executive Director1yrno datano data
Yupeng Zhang
Non-Executive Director1yrno datano data
Yuan Zhou
Non-Executive Director1yrno datano data

2.5yrs

Average Tenure

42.5yo

Average Age

Experienced Board: HO5's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Tian Yuan Healthcare Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Tian Yuan Healthcare Group Limited
  • Ticker: HO5
  • Exchange: DB
  • Founded:
  • Industry: Hotels, Resorts and Cruise Lines
  • Sector: Consumer Services
  • Market Cap: HK$666.296m
  • Listing Market Cap: HK$76.086m
  • Shares outstanding: 398.98m
  • Website: https://www.tianyuanhealthcare.com

Number of Employees


Location

  • China Tian Yuan Healthcare Group Limited
  • Room Nos. 1120-1126
  • 11th Floor
  • Wanchai
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HO5DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
557SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJan 1992

Biography

China Tian Yuan Healthcare Group Limited, an investment holding company, provides hospitality related services in Hong Kong, Korea, the United States, the British Virgin Island, China, Singapore, and Spain. The company operates through four segments: Investment Holding, Hospitality, Healthcare, and Money Lending and Related Business. It offers hotel management services, including annual business planning, operations improvement, sales and marketing consultancy, management of franchise affiliation, human resources management, accounting and budgeting, and asset management services; reservations connectivity; online channel marketing; and revenue/channel management services. The company also offers sceptre hospitality resource, which includes WindsurferCRS that provides optimal functionality for properties; and Whiteboard Labs that provide custom solutions for hospitality industry; and Revenue Management for hire service. In addition, it offers purchasing and procurement services to hotels and to the medical industry; and risk management and insurance services to hotels. Further, the company invests in equity investments; marketable equitable equity mutual funds; and equity funds, as well as owns and manages hotels. Additionally, it licenses trademarks; and provides loans and related services to third parties. It operates 25 hotels with approximately 4,600 rooms under the Hilton, Starwood, Marriott, and Choice International brand names. The company was formerly known as City e-Solutions Limited and changed its name to China Tian Yuan Healthcare Group Limited in November 2017. The company is based in Wanchai, Hong Kong. China Tian Yuan Healthcare Group Limited is a subsidiary of China Tian Yuan Manganese Limited. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 21:31
End of Day Share Price2020/07/10 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.